Subscribe to Newsletter

February 2020 Issue of The Medicine Maker

In February’s cover feature, find out what it takes to develop, safely deliver and commercialize a CAR T cell therapy with Kite Pharma. We ask what the Brexit transition period means for the pharma industry, and in particular, batch release; while Andrew Edwards argues that current market conditions aren’t suited to the development of antibiotics. In addition, find out how greater supply chain transparency will help address shortages, why so many drugs fail the final hurdle, and the benefits and dangers of human germline genome editing. We also sit down with Matthew Todd, Open Source Pharma founder.

Register to download
Register here to download any issue of The Medicine Maker for FREE.
Login
Forgot your password?
Receive content, products, events as well as relevant industry updates from The Medicine Maker and its sponsors.
Stay up to date with our other newsletters and sponsors information, tailored specifically to the fields you are interested in

When you click “Subscribe” we will email you a link, which you must click to verify the email address above and activate your subscription. If you do not receive this email, please contact us at [email protected].
If you wish to unsubscribe, you can update your preferences at any point.

Articles featured in this issue

 Discovery & Development Advanced Medicine

The Patient Is the Priority

| James Strachan

We announce a new Special Series of articles devoted to advanced medicine.
Manufacture Advanced Medicine

Cost of a Cure

| James Strachan

Gene therapies (including CAR T) could add $45 billion to US healthcare costs over the next five years, a CVS health report finds.
Manufacture Advanced Medicine

Advanced Medicine In Brief

| James Strachan

The world’s largest cell and gene CDMO, an exciting new TCR, and the global CAR T picture… We examine what’s going on in advanced medicine.
Discovery & Development Advanced Medicine

Where's the Off Switch?!

| Stephanie Vine

Researchers seek a way to inactivate CAR-T cells in case of adverse effects.
Discovery & Development Drug Delivery

Image of the Month: A Piercing Barb

Engineers from Rutgers used 4D printing to create tiny needles with backward-facing barbs. Could these replace hypodermic needles?
Manufacture Advanced Medicine

Point of Care, Point of Commercialization

| James Strachan

UC Davis joins Orgenesis’ point-of-care network to develop and commercialize cell and gene therapies in house.
Manufacture Clinical Trials

Rising to the ADC Challenge

| Maryam Mahdi

What challenges do manufacturers face in developing ADCs?
Discovery & Development Clinical Trials

Failing Safely: Why Ending Some Programmes Early May Be a Recipe for Successes Later

| Adrian Wildfire

Why are compounds still failing at the final hurdle?
Business & Regulation Business Practice

Greater Transparency; Fewer Shortages

| Dawn MacNeill

Only when greater transparency is established in supply chains can the industry begin to iron out problems with drug shortages.
Manufacture Advanced Medicine

Driving CAR T Cell Therapy

| James Strachan

John Rossi, Director of Translational Sciences at Kite Pharma, talks about bright future of CAR T cell therapy.
Manufacture Advanced Medicine

CAR T Cell Therapy: Redefining Quality

| Bethany Dudek

Here we explore the challenges involved in ensuring CAR T cell therapies are delivered to patients safely and as quickly as possible.
Manufacture Advanced Medicine

How to Commercialize a CAR T Cell Therapy

| James Strachan

Dick Sundh, Head of Europe at Kite, explains what it takes to commercialize CAR T cell therapy.
Manufacture Advanced Medicine

Hands Off the Goods

| Chris Procyshyn

Aseptic filling is the final manufacturing step but it shouldn’t be an afterthought.
Discovery & Development Drug Discovery

Antibiotic Apocalypse: Resistance is (Not) Futile

| Maryam Mahdi

What needs to change to improve our odds in the fight against AMR?
Discovery & Development Drug Delivery

A Matter of (Cellular) Integrity

| Maryam Mahdi

A cell-free biologic could act as platform therapeutic for a variety of serious diseases.
Discovery & Development Drug Discovery

Sharing is Caring

Sitting down with… Matthew Todd, Chair of Drug Discovery at UCL and founder of the Open Source Pharma movement.

Other issues of 2020